2015
Human PrimPol: A Novel Mechanism of Antiviral Toxicity
Mislak A, Anderson K. Human PrimPol: A Novel Mechanism of Antiviral Toxicity. The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.710.23.Peer-Reviewed Original ResearchNucleoside reverse transcriptase inhibitorsAntiviral toxicityHIV-1HIV-1-infected patientsNRTI-associated mitochondrial toxicityDaily drug regimensHIV-1 infectionLife-long administrationReverse transcriptase inhibitorsReduced viral loadReverse transcriptasePrevent viral transmissionDrug regimensViral loadTranscriptase inhibitorsRelated morbidityInfected patientsSevere mitochondrial dysfunctionSide effectsPatient adherenceViral replicationMechanisms of toxicityMitochondrial toxicityViral transmissionPatients
2012
Balancing Antiviral Potency and Host Toxicity: Identifying a Nucleotide Inhibitor with an Optimal Kinetic Phenotype for HIV-1 Reverse Transcriptase
Sohl C, Kasiviswanathan R, Kim J, Pradere U, Schinazi R, Copeland W, Mitsuya H, Baba M, Anderson K. Balancing Antiviral Potency and Host Toxicity: Identifying a Nucleotide Inhibitor with an Optimal Kinetic Phenotype for HIV-1 Reverse Transcriptase. Molecular Pharmacology 2012, 82: 125-133. PMID: 22513406, PMCID: PMC3382833, DOI: 10.1124/mol.112.078758.Peer-Reviewed Original ResearchConceptsNucleoside reverse transcriptase inhibitorsHost toxicityClinical trialsReverse transcriptaseTreatment of HIV infectionMinimal host toxicityUnique toxicity profilePhase II clinical trialReverse transcriptase inhibitorsII clinical trialsHIV-1 reverse transcriptaseWild-typeAntiretroviral efficacyHIV infectionToxicity profileTranscriptase inhibitorsHIV-1Molecular mechanismsTreat HIVMechanisms of toxicityMitochondrial toxicityMolecular mechanisms of toxicityAntiviral potencyViral target proteinsThymidine analog